Zach Hartman
Contributor since: 2015
Latest Articles
3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara's Immunotherapy Data
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
3 Things In Biotech, May 17: Insmed's Approval Chance, Pfizer Finally Proves Similar, Eagle Ascends
3 Things In Biotech, May 16: Lilly's No Headache, Aerie Eye's A Finish, Rexahn Swaps In Pancreatic Cancer
The Ongoing Loxo Thesis, Part 2: The Journey Doesn't End With Larotrectinib
3 Things In Biotech, May 10: AstraZeneca Expands, Roche Digs In, OncoSec Gets A Collab
3 Things In Biotech, May 9: New AML Therapy Imminent? AVEO Hedges, Rockwell Boosts Iron
The Ongoing Loxo Thesis, Part 1: Loxo's Rising Star
3 Things In Biotech, May 8: Roche Moves, Johnson & Johnson Grooves, Valeant Eases
3 Things In Biotech, May 7: Novartis Thyroid Breakout, Redhill's Stomach Bugs, Intra-Cellular Update On Schizoid Drugs
The No BS Report, Week 12: Living In Yawnsville With Little But Gains
3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises
3 Things In Biotech, May 4: Merck's New Combo, Alnylam Jump Starts, Ocata Gone Forever?
3 Things In Biotech, May 3: Bristol Bows Out Of IDO, And Two Biotechs Look To Investigate Novel Immunotherapies
3 Things In Biotech, May 2: Big CARs, Big Kar Lands, Amgen Advances
3 Things In Biotech, May 1: Merck's Horizons, Pluristem's Nod, Reg/San Look To Break In
3 Things In Biotech, April 30: Another ADC, Another Breakthrough, Another Immunotherapy
3 Things In Biotech, April 29: Bristol-Myers Widens, Ono Takes On Pheo, BrainStorm's ALS Adventure Moves Forward
The No BS Report, Week 11: Rising Tides And Sinking Ships?
3 Things In Biotech, April 28: Fighting Mental Disorders, And A New Strategy For Bacteria?
3 Things In Biotech, April 27: AbbVie And Alexion Move Forward, ADC Moves Back
3 Things In Biotech, April 26: Taking The Bad With The Good
3 Things In Biotech, April 25: Biogen Advances, Prothena Crashes, Lilly Survives
3 Things In Biotech, April 24: A Good, A Bad, And A Strong Maybe
Bristol-Myers And Exelixis Poise For Battle In Kidney Cancer - Who Will Emerge The Victor?
3 Things In Biotech, April 23: Support, Support, And Those Blasted Blood Vessels
3 Things In Biotech, April 22: All These 'A' Companies
The No BS Plan Report, Week 10: Where The Reliable Falter
3 Things In Biotech, April 21: Solid Stands, Argos Stops, NewLink Strives
3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close
3 Things In Biotech, April 19: Let's Talk Genito-Urinary Cancer
3 Things In Biotech, April 18: Bristol Plows Ahead, Celldex Flops, Alkermes Gets A Surprise